HOC people: Patti Peeples Gustafson, PhD
By David Woods (david.woods@rxcomms.com) Dr. Patti Peeples: what a perfect name for the subject of HOC people! She tells me that the origin of the name is from Peebles, in…
Is big pharma becoming big biotech?
Recent reports in the Wall Street Journal and The Economist describe an imminent seismic shift in business models for pharmaceutical companies, as current blockbuster drugs are set to go off-patent and a rapidly dwindling pipeline of new drugs are under development or are being reviewed for approval.
A new way for pharmaceutical companies and prescribers to interact?
By David Woods (david.woods@rxcomms.com) Call them Sermoans, Sermophiles, or just plain members, the 32,000 physicians enrolled in Sermo could be changing the way that pharmaceutical companies interact with healthcare professionals.…
You need to know the global issues in health economics
By Robert Hand (robert.hand@rxcomms.com) As a health economist and outcomes researcher, you may work primarily within a single country. Naturally, you know the economic, regulatory, and management issues of that…
HOC people – Dennis M. Gross, PhD
By David Woods (david.woods@rxcomms.com) On January 1st 2006, Dr Dennis Gross retired from Merck after 28 years; the following day, he took up his present position as Associate Dean, Masters…
Letter to the editor
Our HOC People person this month, Dennis M. Gross, PhD, is an associate dean at Thomas Jefferson University where he also teaches courses in pharmacology and toxicology. He emailed us these thoughts on non-adherence.
Making adherence work for your dollar (or pound, or euro…)
By Mary Gabb (mary.gabb@rxcomms.com) As we reported in last month’s HOC, the past few years have witnessed a surge of interest in the role of adherence in health economics research,…
The “other drug costs” – Part 1: non-adherence
By Mary Gabb (mary.gabb@rxcomms.com) The term “adherence” (or sometimes “compliance”) – the extent to which patients take their treatment as prescribed – has been understood to be a nagging clinical…
HOC people – David B. Nash, MD, MBA
By David Woods (david.woods@rxcomms.com) US News and World Report calls him a patient safety guru; Modern Healthcare has repeatedly named him among the top 100 most powerful people in American…
HOC people – Diana Brixner
By David Woods (david.woods@rxcomms.com) Newly-installed ISPOR president Diana Brixner, RPh, PhD, has put together a challenging agenda for the society during her term of office. The central point of that…